// App-Quantinova.ai

14 : Phase II study evaluating trifluridine/tipiracil + bevacizumab and capecitabine + bevacizumab in first-line unresectable metastatic colorectal cancer (mCRC) patients who are noneligible for intensive therapy (TASCO1): Results of the final analysis on the overall survival.

Researchers

Presenter

  • Eric Van Cutsem

Principal Investigators

  • Mark P. Saunders

  • Per Pfeiffer

  • Guillem Argiles

  • Christophe Borg

  • Robert Glynne-Jones

  • Cornelis J. A. Punt

  • Agnes J. van de Wouw

  • Mikhail Fedyanin

  • Daniil Stroyakovskiy

  • Hendrik Kroening

  • Pilar Garcia-Alfonso

  • Harpreet Singh Wasan

  • Alfredo Falcone

  • Paul Aubel

  • Anton Egorov

  • Nadia Amellal

  • Vladimir Moiseenko

Medical Centers

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • Szpitale Wojewodzkie w Gdyni/Gdansk Medical University, Gdynia, Poland

  • The Christie NHS Foundation TRUST, Manchester, United Kingdom

  • Department of Oncology, Odense University Hospital, Odense, Denmark

  • Vall dHebron University Hospital and Institute of Oncology (VHIO), CIBERONC, TTD Group, Barcelona, Spain

  • Department of Medical Oncology, Besancon University Hospital, Besancon, France

  • Mount Vernon Cancer Centre, Middlesex, United Kingdom

  • Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands

  • Viecuri Medical Centre, Venlo, Netherlands

  • Federal State Budgetary Institution "N.N. Blokhin National Medical Research Center of Oncology"оf the Ministry of Health of the Russian Federation (N.N. Blokhin NMRCO), Moscow, Russian Federation

  • 62nd Moscow Oncological Hospital, Moscow, Russian Federation

  • Schwerpunktpraxis für Hämatologie und Onkologie, Magdeburg, Germany

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Hammersmith Hospital, Division of Cancer, Imperial College London, London, United Kingdom

  • Azienda Ospedaliero Universitaria Pisana, Pisa, Italy

  • Institut de Recherches Internationales Servier, Suresnes, France

  • Saint-Petersburg Scientific Practical Center for Specialized Medical Care, Saint-Petersburg, Russian Federation

Locations

  • Belgium

  • Poland

  • United Kingdom

  • Denmark

  • Spain

  • France

  • Netherlands

  • Russia

  • Germany

  • Italy

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Tipiracil and trifluridine

  • Capecitabine

  • Trifluridine

  • Bevacizumab

Outcome

  • N/A

Study Design

  • Randomized

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved